(Hypertension. 2002;39:224.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Institut National de la Santé et de la Recherche Médicale Unité 36, Pathologie Vasculaire et Endocrinologie Rénale, Chaire de Médecine Expérimentale, Collège de France, Paris, France.
Correspondence to Dr Pierre Corvol, INSERM U36Collège de France, 11, place Marcelin Berthelot, 75231 Paris Cedex 05, France. E-mail pierre.corvol{at}college-de-france.fr
The members of the serine protease inhibitor (serpin) family, which share a common tertiary structure and a role as serin protease inhibitors, are involved in a variety of newly discovered functions. For example, antithrombin III exerts a strong antiangiogenic activity. Angiotensinogen, the renin substrate, has a folded structure and is a member of the noninhibitory serpin subfamily. Two other noninhibitory serpins, maspin and pigment epithelium-derived factor, have antiangiogenic properties. We investigated the antiangiogenic effect of angiotensinogen and 2 related compounds: (1) des(angiotensin I)angiotensinogen, the product of angiotensinogen cleavage by renin, and (2) the reactive center loop-cleaved angiotensinogen, which is produced after selective and limited proteolysis by the protease V8. We used well-established in vitro (endothelial cell proliferation and migration, and capillary-like tube formation on Matrigel) and in vivo (the chick chorioallantoic membrane assay) models of angiogenesis to evaluate the antiangiogenic activities of these 3 related molecules. Our data demonstrated that these compounds exerted a clear and equipotent antiangiogenic effect, thus attributing a novel function to angiotensinogen and des(angiotensin I)angiotensinogen, for which no function was previously known.
Key Words: angiotensinogen angiotensin I endothelial growth factors
This article has been cited by other articles:
![]() |
F. Vincent, P. Bonnin, M. Clemessy, J.-O. Contreres, N. Lamande, J.-M. Gasc, J. Vilar, P. Hainaud, G. Tobelem, P. Corvol, et al. Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice Cancer Res., April 1, 2009; 69(7): 2853 - 2860. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Karagiannis and A. S. Popel A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells PNAS, September 16, 2008; 105(37): 13775 - 13780. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. de Sa, M. L. Correa-Giannella, M. C. Machado, K. Krogh, M. Q. de Almeida, M. A. Albergaria Pereira, S. A. Coelho Siqueira, R. A. Patzina, F. S. Ibuki, M. C. Sogayar, et al. Serpin Peptidase Inhibitor Clade A Member 1 as a Potential Marker for Malignancy in Insulinomas Clin. Cancer Res., September 15, 2007; 13(18): 5322 - 5330. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sugimoto, T. Furuta, N. Shirai, C. Kodaira, M. Nishino, M. Ikuma, H. Sugimura, and A. Hishida Role of angiotensinogen gene polymorphism on Helicobacter pylori infection-related gastric cancer risk in Japanese Carcinogenesis, September 1, 2007; 28(9): 2036 - 2040. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brand, N. Lamande, C. D. Sigmund, E. Larger, P. Corvol, and J.-M. Gasc Angiotensinogen Modulates Renal Vasculature Growth Hypertension, June 1, 2006; 47(6): 1067 - 1074. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. W. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma Adipokines: molecular links between obesity and atheroslcerosis Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2031 - H2041. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sherrod, X. Liu, X. Zhang, and C. D. Sigmund Nuclear localization of angiotensinogen in astrocytes Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2005; 288(2): R539 - R546. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Larger, M. Marre, P. Corvol, and J.-M. Gasc Hyperglycemia-Induced Defects in Angiogenesis in the Chicken Chorioallantoic Membrane Model Diabetes, March 1, 2004; 53(3): 752 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Daly, A. Makris, M. Reed, and C. E. Lewis Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment? J Natl Cancer Inst, November 19, 2003; 95(22): 1660 - 1673. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Re Intracellular Renin and the Nature of Intracrine Enzymes Hypertension, August 1, 2003; 42(2): 117 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Re Implications of intracrine hormone action for physiology and medicine Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H751 - H757. [Full Text] [PDF] |
||||
![]() |
C. Emanueli and P. Madeddu Letter to the Editor: Renin-Angiotensin and Kallikrein-Kinin Systems Coordinately Modulate Angiogenesis Hypertension, June 1, 2002; 39 (6): e29 - e29. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |